Knickerbocker Dialysis, Inc. is a medicare approved dialysis facility center in Syracuse, New York and it has 30 dialysis stations. It is located in Onondaga county at 910 Erie Boulevard East, Syracuse, NY, 13210. You can reach out to the office of Knickerbocker Dialysis, Inc. at (315) 410-8040. This dialysis clinic is managed and/or owned by Davita. Knickerbocker Dialysis, Inc. has the following ownership type - Profit. It was first certified by medicare in December, 2000. The medicare id for this facility is 332615 and it accepts patients under medicare ESRD program.
| Name | Knickerbocker Dialysis, Inc. |
|---|---|
| Location | 910 Erie Boulevard East, Syracuse, New York |
| No. of Dialysis Stations | 30 |
| Medicare ID | 332615 |
| Managed By | Davita |
| Ownership Type | Profit |
| Late Shifts | No |
| 910 Erie Boulevard East, Syracuse, New York, 13210 | |
| (315) 410-8040 | |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| NPI Number | 1285978999 |
| Organization Name | Central New York Dialysis Center |
| Doing Business As | Knickerbocker Dialysis Inc |
| Address | 910 Erie Blvd E Syracuse, New York, 13210 |
| Phone Number | (315) 410-8040 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| NPI Number | 1932271251 |
| Doing Business As | Central New York Dc, Llc |
| Address | 910 Erie Blvd E Syracuse, New York, 13210 |
| Phone Number | (315) 410-8040 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that nephrologists always communicated and cared for them. | 65% | 67% |
| Patients who reported that nephrologists usually communicated and cared for them. | 17% | 15% |
| Patients who reported that nephrologists sometimes or never communicated and cared for them. | 18% | 18% |
| Patients who gave their nephrologists a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 70% | 60% |
| Patients who gave their nephrologists a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 20% | 26% |
| Patients who gave their nephrologists a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 10% | 14% |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that dialysis center staff always communicated well, kept patients comfortable and pain-free as possible. | 52% | 62% |
| Patients who reported that dialysis center staff usually communicated, kept patients comfortable and pain-free as possible. | 17% | 20% |
| Patients who reported that dialysis center staff sometimes or never communicated, kept patients comfortable and pain-free. | 31% | 18% |
| Patients who gave their dialysis facility staff a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 55% | 62% |
| Patients who gave their dialysis facility staff a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 26% |
| Patients who gave their dialysis facility staff a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 24% | 12% |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| Experience Measure | Provider | National Avg. |
|---|---|---|
| Patients who reported that 'YES', their nephrologists and dialysis center staff provided them the information they needed to take care of them. | 80% | 80% |
| Patients who reported that 'NO', their nephrologists and dialysis center staff does not provided them the information they needed to take care of them. | 20% | 20% |
| Patients who gave their dialysis center a rating of 9 or 10 on a scale of 0 (worst possible) to 10 (best possible). | 53% | 68% |
| Patients who gave their dialysis center a rating of 7 or 8 on a scale of 0 (worst possible) to 10 (best possible). | 26% | 20% |
| Patients who gave their dialysis center a rating of 6 or less than 6 on a scale of 0 (worst possible) to 10 (best possible). | 21% | 12% |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| Dialysis patients with Hemoglobin data | 82 |
| Medicare patients who had average hemoglobin (hgb) less than 10 g/dL | 15 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
Adult patinets who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be atleast 1.7, that means they are receiving right amount of dialysis. Pediatric patients who undergo hemodialysis, their Kt/V should be atleast 1.2 and for peritoneal dialysis the Kt/V should be 1.8.
Higher percentages should be better.
| Adult patients getting regular hemodialysis at the center | 135 |
| Adult patient months included in Kt/V greater than or equal to 1.2 | 1201 |
| Percentage of adult patients getting regular hemodialysis at the center | 93 |
| Percentage of pediatric patients getting regular hemodialysis at the center |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
| Adult patients getting regular peritoneal dialysis at the center | 44 |
| Adult patient months included in Kt/V greater than or equal to 1.7 | 337 |
| Percentage of adult patients getting regular peritoneal dialysis at the center | 94 |
| Percentage of pediatric patients getting regular peritoneal dialysis at the center |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
An important goal of dialysis is to maintain normal levels of various minerals in the body, such as calcium. This shows the percentage of patients treated at Knickerbocker Dialysis, Inc. with elevated calcium levels.
| Patients with hypercalcemia | 179 |
| Hypercalcemia patient months | 1615 |
| Hypercalcemia patients with serumcalcium greater than 10.2 mg | 1 |
| Patients with Serumphosphor | 185 |
| Patients with Serumphosphor less than 3.5 mg/dL | 9 |
| Patients with Serumphosphor from 3.5 to 4.5 mg/dL | 23 |
| Patients with Serumphosphor from 4.6 to 5.5 mg/dL | 33 |
| Patients with Serumphosphor from 5.6 to 7 mg/dL | 21 |
| Patients with Serumphosphor greater than 7 mg/dL | 13 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
The arteriovenous (AV) fistulae is considered long term vascular access for hemodialysis because it allows good blood flow, lasts a long time, and is less likely to get infected or cause blood clots than other types of access. Patients who don't have time to get a permanent vascular access before they start hemodialysis treatments may need to use a venous catheter as a temporary access.
| Patients included in arterial venous fistula and catheter summaries | 110 |
| Patient months included in arterial venous fistula and catheter summaries | 903 |
| Percentage of patients getting regular hemodialysis at the center that used an arteriovenous (AV) fistulae for their treatment | 64 |
| Percentage of patients receiving treatment through Vascular Catheter for 90 days/longer | 10 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
The rate of hospitalization show you whether patients who were being treated regularly at a certain dialysis center were admitted to the hospital more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other centers.
| Standard Hospitalization Summary Ratio(SHR) Year | January, 2016 - December, 2016 |
| Patients in facility's Hospitalization Summary | 158 |
| Hospitalization Rate in facility | 183.5 (As Expected) |
| Hospitalization Rate: Upper Confidence Limit | 275.1 |
| Hospitalization Rate: Lower Confidence Limit | 130.1 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
The rate of readmission show you whether patients who were being treated regularly at Knickerbocker Dialysis, Inc. were readmitted more often (worse than expected), less often (better than expected), or about the same (as expected), compared to similar patients treated at other dialysis centers.
| Standard Readmission Summary Ratio(SRR) Year | January, 2016 - December, 2016 |
| Readmission Rate in facility | 26.4 (As Expected) |
| Readmission Rate: Upper Confidence Limit | 36.7 |
| Readmission Rate: Lower Confidence Limit | 17.7 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
Hemodialysis treatment requires direct access to the bloodstream, which can be an opportunity for germs to enter the body and cause infection. This information shows how often patients at Knickerbocker Dialysis, Inc. get infections in their blood each year compared to the number of infections expected for the center based on the national average.
| Standard Infection Summary Ratio(SIR) Year | January, 2016 - December, 2016 |
| Infection Rate in facility | 1.61 (As Expected) |
| SIR: Upper Confidence Limit | 2.69 |
| SIR: Lower Confidence Limit | .9 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
Patients with anemia require blood transfusions if their anemia is not managed well by their dialysis center. This information shows whether Knickerbocker Dialysis, Inc.'s rate of transfusions is better than expected, as expected, or worse than expected, compared to other centers that treat similar patients.
| Standard Transfusion Summary Ratio (STrR) Year | January, 2016 - December, 2016 |
| Patients in facility's Transfusion Summary | 143 |
| Transfusion Rate in facility | 46.7 (As Expected) |
| Transfusion Rate: Upper Confidence Limit | 81.1 |
| Transfusion Rate: Lower Confidence Limit | 28.8 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
The rate of mortality show you whether patients who were being treated regularly at Knickerbocker Dialysis, Inc. lived longer than expected (better than expected), don’t live as long as expected (worse than expected), or lived as long as expected (as expected), compared to similar patients treated at other facilities.
| Standard Survival Summary Ratio(SIR) Year | January, 2013 - December, 2016 |
| Patients in facility's Survival Summary | 962 |
| Mortality Rate in facility | 15.7 (As Expected) |
| Mortality Rate: Upper Confidence Limit | 18.8 |
| Mortality Rate: Lower Confidence Limit | 13 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago
University Dialysis Center Location: 1127 East Genesee Street, Syracuse, New York, 13210 Phone: (315) 473-5100 |
Knickerbocker Dialysis, Inc. Location: 910 Erie Boulevard East, Syracuse, New York, 13210 Phone: (315) 410-8040 |
Liverpool Dialysis Center, Llc Location: 1304 Buckley Road, Syracuse, New York, 13212 Phone: (315) 671-9950 |
News Archive
When people suffer debilitating injuries or illnesses of the nervous system, they sometimes lose the ability to perform tasks normally taken for granted, such as walking, playing music or driving a car. They can imagine doing something, but the injury might block that action from occurring.
Promedior, Inc., a clinical stage biotechnology company developing novel therapies to treat inflammatory and fibrotic diseases, today announced that it has raised $12 million in a Series C financing round. Forbion Capital Partners led the round, with participation from existing investors Morgenthaler Ventures, HealthCare Ventures, Polaris Venture Partners, and Easton Capital. The Series C financing brings the total capital raised by Promedior over the past year to $27 million.
Cytokinetics, Incorporated and The ALS Association announced an expanded partnership in which the company will provide Gold Level Sponsorship of the National Walks to Defeat ALS as well as Platinum Level Sponsorship for ALS Association Golden West Chapter initiatives.
Groundbreaking research from the University of Alberta has identified the structure of the infectious prion protein, the cause of "mad cow disease" or BSE, chronic wasting disease in deer and elk and Creutzfeldt-Jakob disease in humans, which has long remained a mystery.
› Verified 3 days ago